Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;22(11):757-766.
doi: 10.1007/s11910-022-01230-6. Epub 2022 Oct 1.

Cerebrovascular Disease, Cardiovascular Disease, and Chronic Kidney Disease: Interplays and Influences

J David Spence  1 , Bradley L Urquhart  2
Affiliations
Review

Cerebrovascular Disease, Cardiovascular Disease, and Chronic Kidney Disease: Interplays and Influences

J David Spence et al. Curr Neurol Neurosci Rep. 2022 Nov.

Abstract

Purpose of review: We reviewed reasons for the high cardiovascular risk (CVD) of patients with chronic kidney disease (CKD), and explored alternatives to treatment of traditional risk factors to reduce CVD in CKD.

Recent findings: Besides traditional risk factors, patients with CKD are exposed to uremic toxins of two kinds: systemically derived toxins include asymmetric dimethylarginine (ADMA), total homocysteine (tHcy), thiocyanate, tumor necrosis factor alpha, and interleukin 6. Gut-derived uremic toxins (GDUT), products of the intestinal microbiome, include hippuric acid, indoxyl sulfate, p-cresyl sulfate, p-cresyl glucuronide, phenylacetylglutamine, and trimethylamine N-oxide (TMAO). Cyanocobalamin is toxic in patients with CKD. Approaches to reducing plasma levels of these uremic toxins would include diet to reduce GDUT, kidney transplantation, more intensive dialysis, and vitamin therapy to lower tHcy with methylcobalamin rather than cyanocobalamin. The high CVD risk in CKD requires consideration of therapies beyond treatment of traditional risk factors.

Keywords: Cardiovascular risk; Chronic kidney disease; Dialysis; Diet; Intestinal microbiome; Uremic toxins.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Wheeler DC. Cardiovascular disease in patients with chronic renal failure. Lancet. 1996;348(9043):1673–4. - DOI - PubMed
    1. Sozio SM, Armstrong PA, Coresh J, Jaar BG, Fink NE, Plantinga LC, et al. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOICE) study. Am J Kidney Dis. 2009;54(3):468–77. https://doi.org/10.1053/j.ajkd.2009.01.261 . - DOI - PubMed - PMC
    1. •• Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–52. https://doi.org/10.1016/S0140-6736(13)60595-4 . An important paper that quantifies cardiovascular risk by severity of CKD. - DOI - PubMed
    1. Bowman B, Abdel-Rahman EM. Cardiovascular outcomes in dialysis patients: one size does not fit all. Eur Heart J. 2019;40(11):899–901. https://doi.org/10.1093/eurheartj/ehy544 . - DOI - PubMed
    1. • Ku E, McCulloch CE, Ahearn P, Grimes BA, Mitsnefes MM. Trends in cardiovascular mortality among a cohort of children and young adults starting dialysis in 1995 to 2015. JAMA Netw Open. 2020;3(9):e2016197. https://doi.org/10.1001/jamanetworkopen.2020.16197 . Secular trends of CVD mortality in dialysis patients. - DOI - PubMed - PMC

MeSH terms